Less than two months after Farallon Capital Management filed a proxy race to fill three board seats at cancer biotech company Exelixis, he was awarded what he sought at the company’s annual shareholder meeting.
The hedge fund said Wednesday that the initial effects of Exelixis’ annual shareholder meeting elected Farallon’s 3 nominees to the board: Tom Heyman, Dave Johnson and Bob Oliver.
Unlock this item and others by subscribing to one of our paid plans.
We live in a new era of healthcare that advances and impacts patient outcomes and experiences. We have noticed a remarkable speed of transformative innovation, implemented studies, and complex clinical progression over the past decade.
Despite this great progress, there is still much work to be done and patients are counting on us, now more than ever, to continue this momentum. challenging diseases, adding those that today have few or no effective remedies.
As a number of gene treatment startups aim to create remedies without the inevitable back and forth of an AAV virus, and several gene-editing biotechnologies seek to do the same, the said venture is coming to an end.
Summation Bio, subsidized through at least $24 million in Series A funding, is “shutting down operations” next month, according to an update to a worker’s LinkedIn profile. (According to his LinkedIn profile, one worker said the company raised $60 million in the round. )Another worker visited the networking site last week to say the cases were “second to none” and noted that “despite all efforts and error-free execution, the science, this time, was elusive. “
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Eikon Therapeutics on Thursday announced three advertising growth deals, launching a pipeline of cancer drugs for more than $100 million in new funding.
The Hayward, California-based company has one of the richest biotech startups since its founding in 2019, having raised nearly $775 million. Cells and proteins practice in action. After its Series B last year, PitchBook reported a valuation of $3. 02 billion. “a significant advance over our valuation of Series B. “
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
After forging a series of partnerships over the years, Dutch antibody and drug conjugate specialist Synaffix has a new home: Lonza, the developer and giant of contract production.
Lonza is paying around $107 million (€100 million) in money to get Synaffix, with up to $64 million (€60 million) in “additional performance-based consideration” on the table. Synaffix’s ADC generation platform will now be a component of Lonza’s supply for biopharmaceutical customers, lending its bioconjugate technologies only to ADCs, but also to targeted gene therapy, mobile immune activators and other applications.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
We’ve replaced our calendar of events in Boston next week, where we’ll host a combination of live/broadcast events at our Seaport Hotel base as part of a two-day lineup of webinars, virtual vigils, and a Q&A session. Cocktail with a veteran of the biotech finance scene.
The live space from 9:30 a. cómo. Se confirms to Alaa Halawa, head of US corporations. He is a U. S. citizen at Mubadala, as well as Brian Goodman at MPM and Geoff von Maltzahn, general spouse at Moderna powered by Flagship. I have a few other invitations and will let you know how it goes. .
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Embarking on a private project after the mother of his most productive friend was diagnosed with mutation-induced frontotemporal dementia, Michael Horowitz raised $8 million in venture capital investment for Modulo Bio to create small molecules for neurodegenerative diseases.
The San Diego and Bay Area biotech will be its leading progression candidate and some backup functions within six months, and will then launch a Series A to investigate therapy for C9orf72-induced ALS and frontotemporal dementia, Horowitz told Endpoints News.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
AstraZeneca is shelving an IL-23 antibody that has gone through a winding adventure through the pharmaceutical industry, adding stops at Amgen and Allergan, and ending phase II and III trials testing the drug for inflammatory bowel disease.
“The resolution to discontinue the progression of brazikumab IBD follows a recent review of the timeline of progression of brazikumab and the context of a competitive landscape that has continued to evolve,” the press said.
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
In April, an FDA announcement approved the expansion of Lynparza, a successful PARP inhibitor from AstraZeneca, into prostate cancer, but for patients with BRCA tumors.
On Wednesday, the FDA followed the advice of adcomm and Lynparza in combination with abiraterone (Zytiga) and prednisone or prednisolone for adult patients with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC).
Unlock this story right away and sign up for over 170,400 biopharmaceutical professionals to read Endpoints daily, and it’s free.
Pfizer’s once-weekly antibody treatment for hemophilia A and B helped reduce bleeding cases in patients compared to its previous treatment of infusions of blood-clotting things, the pharmaceutical company announced Tuesday morning.
The open-label phase III study enrolled another 116 people with hemophilia who were first treated for six months with normal or on-demand infusions of thing VIII or IX, the clotting things that hemophilia A and B patients lack. Then, either team switched to the remedy once a week with Pfizer’s marstacimab antibody for a year.
Unlock this item and others by subscribing to one of our paid plans.
© Endpoints 2023 News
We will email you a link to set a new password. Please note that this link is for single use and is valid for 24 hours.